Drug Profile
Research programme: immunotherapies - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical Center
Alternative Names: Immuno-oncology therapeutics - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical CenterLatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Immune-Onc Therapeutics; University of Texas Health Science Center at Houston; University of Texas Southwestern Medical Center
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Leukocyte-associated immunoglobulin-like receptor 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- No development reported Immunological disorders
Most Recent Events
- 12 Mar 2020 No development reported for Immunological disorders in USA (Parenteral)
- 12 Mar 2020 Preclinical trials in Cancer in USA (Parenteral) before March 2020 (Immune-Onc Therapeutics pipeline March 2020)
- 18 Apr 2017 Immune-Onc Therapeutics enters into an exclusive license and collaboration agreement with University of Texas Health Science Center at Houston and University of Texas Southwestern Medical Center to develop biotherapeutics for Cancer and other Immunological disorders